share_log

Morgan Stanley Downgrades Akoya Biosciences to Equalweight From Overweight, Adjusts PT to $3 From $4

Morgan Stanley Downgrades Akoya Biosciences to Equalweight From Overweight, Adjusts PT to $3 From $4

摩根士丹利将Akoya Biosciences的评级下调至等重,从超重调整目标价为3美元,而不是4美元。
MT Newswires ·  08/06 12:36

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发